Abstract
Disease-modifying therapies are being developed for Alzheimer’s disease (AD). These are expected to slow the clinical progression of the disease or delay its onset. Cerebral accumulation of amyloid β (Aβ) peptides is an early and perhaps necessary event for establishing AD pathology. Consequently therapies aimed at attenuating brain amyloidosis are expected to be disease modifying. Based on the epidemiological evidence pointing to a link between cholesterol metabolism and AD and the numerous laboratory studies implicating cholesterol in the process of Aβ production and accumulation, it is now believed that cholesterol-lowering therapies will be of value as disease modifying agents. Several epidemiological studies revealed that statin use for the treatment of coronary arterial disease is associated with a decreased prevalence or a decreased risk of developing AD. These observations require both preclinical and clinical validation. The former involves testing statins in one or more animal models of AD in order to establish which disease features are affected by statin treatment, the relative efficacy with which different statins modify these features and the mechanism(s) by which statins affect AD phenotypes. The latter requires prospective, randomized, placebo controlled trials to evaluate the effect of statin treatment on cognitive and AD biomarker outcomes. We have initiated a study aimed at determining the effects of atorvastatin (LipitorR), a statin with the largest US market share, on brain Aβ deposition in the PSAPP transgenic mouse model of Alzheimer’s amyloidosis. Our results indicate that Lipitor treatment markedly attenuates Aβ deposition in this animal model.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Akiyama H., Barger S., Barnum S., et al. (2000) Inflammation and Alzheimer’s disease. Neurobiol. Aging 21, 383–421.
Bodovitz S. and Klein W. L. (1996) Cholesterol modulates alpha-secretase cleavage of amyloid precursor protein. J. Biol. Chem. 271, 4436–4440.
Blumenthal R. S. (2000) Statins: effective antiatherosclerotic therapy. Am. Heart 4, 577–583.
Cucchiara B. and Kasner S. E. (2001) Use of statins in CNS disorders. J. Neurol. Sci. 187, 81–89.
Evans R. M., Emsley C. L., Gao S., Sahota A., Hall K. S., Farlow M. R., and Hendrie H. (2000) Serum cholesterol, APOE genotype, and the risk of Alzheimer’s disease: a population-based study of African Americans. Neurology 54, 240–242.
Fassbender K., Simons M., Bergmann C., et al. (2001) Simvastatin strongly reduces levels of Alzheimer’s disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc. Natl. Acad. Sci. USA 98, 5856–5861.
Frears E. R., Stephens D. J., Walters C. E., Davies H., and Austen B. M. (1999) The role of cholesterol in the biosynthesis of beta-amyloid. Neuroreport 10, 1699–1705.
Friedhoff L. T., Cullen E. I., Geoghagen N. S., et al. (2001) Treatment with controlled-release lovastatin decreases serum concentrations of human beta-amyloid (A beta) peptide. Int. J. Neuropsychopharmacol. 4, 127–130.
Hamelin B. A. and Turgeon J. (1998) Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol. Sci. 19, 26–37.
Howland D. S., Trusko S. P., Savage M. J., et al. (1998) Modulation of secreted beta-amyloid precursor protein and amyloid beta-peptide in brain by cholesterol. J. Biol. Chem. 273, 16576–16582.
Holcomb L., Gordon M. N., McGowan E., et al. (1998) Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat. Med. 4, 97–100.
Hutton M., Perez-Tur J., and Hardy J. (1998) Genetics of Alzheimer’s disease. Essays Biochem. 33, 117–131.
Jarvik G. P., Austin M. A., Fabsitz R. R., et al. (1994) Genetic influences on age-related change in total cholesterol, low-density lipoprotein-cholesterol, and triglyceride levels: longitudinal apolipoprotein E genotype effects. Genet. Epidemiol. 11, 375–384.
Jarvik G. P., Wijsman E. M., Kukull W. A., et al. (1995) Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer’s disease: a case-control study. Neurology 45, 1092–1096.
Jick H., Zornberg G. L., Jick S. S., Seshadri S., and Drachman D. A. (2000) Statins and the risk of dementia. Lancet 356, 1627–1631.
Kalmijn S., Launer L. J., Ott A., et al. (1997) Dietary fat intake and the risk of incident dementia in the Rotterdam Study. Ann. Neurol. 42, 776–782.
Maron D. J., Fazio S., and Linton M. F. (2000) Current perspectives on statins. Circulation 101, 207–213.
Mizuno T., Haass C., Michikawa M., et al. (1998) Cholesterol-dependent generation of a unique amyloid beta-protein from apically missorted amyloid precursor protein in MDCK cells. Biochim. Biophys. Acta 1373, 119–130.
Moghadasian M. H. (1999) Clinical pharmacology of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Life Sci. 13, 1329–1337.
Notkola I. L., Sulkava R., Pekkanen J., et al. (1998) Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer’s disease. Neuroepidemiology 17, 14–20.
Puglielli L., Konopka G., Pack-Chung E., et al. (2001) Acylcoenzyme A: cholesterol acyltransferase modulates the generation of the amyloid beta-peptide. Nat. Cell Biol. 905–912.
Refolo L. M., Pappolla M. A., Malester B., et al. (2000) Hypercholesterolemia accelerates the Alzheimer’s amyloid pathology in a transgenic mouse model. Neurobiol. Dis. 7, 321–331.
Refolo L. M., Pappolla M. A., LaFrancois J., et al. (2001) A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer’s disease. Neurobiol. Dis. 5, 890–899.
Roher A. E., Kuo Y. M., Kokjohn K. M., et al. (1999) Amyloid and lipids in the pathology of Alzheimer disease. Amyloid 6, 136–145.
Simons M., Keller P., De Strooper B., et al. (1998) Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc. Natl. Acad. Sci. USA 95, 6460–6464.
Sparks D. L., Scheff S. W., Hunsaker J. C., et al. (1994) Induction of Alzheimer’s-like beta-amyloid immunore-activity in brains of rabbits with dietary cholesterol. Exp. Neurol. 126, 88–94.
Sparks D. L. (1997) Coronary artery disease, hypertension, ApoE, and cholesterol: a link to Alzheimer’s disease? Ann. NY Acad. Sci. 826, 128–146.
Sparks D. L., Martin T. A., Gross D. G., and Hunsaker J. C. III (2000) Link between heart disease, cholesterol, and alzheimer’s disease: a review. Microscopy Res. Technique 50, 287–290.
Tokuda T., Tamaoka A., Matsuno S., et al. (2001) Plasma levels of amyloid beta proteins did not differ between subjects taking statins and those not taking statins. Ann. Neurol. 49, 546–547.
Wolozin B., Kellman W., Ruosseau P., et al. (2000) Decreased prevalence of Alzheimer’s disease associated with 3-hydroxy3-methylglutaryl coenzyme A reductase inhibitors. Arch. Neurol. 57, 1439–1443.
Wolozin B. (2001) A fluid connection: cholesterol and Abeta. Proc. Natl. Acad. Sci. USA 98, 5371–5373.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Petanceska, S.S., DeRosa, S., Olm, V. et al. Statin therapy for Alzheimer’s disease. J Mol Neurosci 19, 155–161 (2002). https://doi.org/10.1007/s12031-002-0026-2
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s12031-002-0026-2